INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $28.92 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-02-22
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-06-30 was $29.80, a 3.62% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $28.82, a 54.74% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $28.76, a 40.63% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $63.67, a 73.77% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $28.92, a 49.47% decline from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $57.23, a 5.81% increase from fiscal 2021.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $54.09, a 496.36% increase from fiscal 2020.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $9.07, a 1.52% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $28.92 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $28.92 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $29.80 10-Q · filed 2023-08-03 | $28.92 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $28.82 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $57.23 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $57.23 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $28.76 10-Q · filed 2023-08-03 | $57.23 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $63.67 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $54.09 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $105.17 10-Q · filed 2022-11-03 | $50.73 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $48.44 10-Q · filed 2022-08-04 | $38.70 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $36.64 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $9.07 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $13.38 10-Q · filed 2021-11-04 | $8.55 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $9.04 10-Q · filed 2021-08-05 | $8.16 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $7.96 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $9.21 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $9.66 10-Q · filed 2020-11-05 | $9.21 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $9.22 10-Q · filed 2020-08-06 | $9.07 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $8.94 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $15.05 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $21.29 10-Q · filed 2019-10-31 | $18.19 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $16.64 10-Q · filed 2019-08-01 | $17.94 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $18.28 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $12.43 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $13.45 10-Q · filed 2018-10-31 | $10.73 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | $11.47 10-Q · filed 2018-08-01 | $10.51 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $10.38 10-Q · filed 2018-05-01 | |||
| 2016-12-31 | $6.48 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $14.91 10-Q · filed 2017-10-31 | $6.42 10-Q · filed 2017-10-31 | ||
| 2016-06-30 | $13.57 10-Q · filed 2017-08-01 | $6.07 10-Q · filed 2017-08-01 | ||
| 2016-03-31 | $4.98 10-Q · filed 2017-05-02 | |||
| 2015-12-31 | $4.24 10-K · filed 2018-03-14 | |||
| 2015-09-30 | $3.97 10-Q · filed 2016-11-01 | $3.97 10-Q · filed 2016-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |